Copyright © 2001 by the European Society of Cardiology.
Letters to the Editor
Comments on EMIP-FR study's editorial
Ischaemic Heart Disease Department, National Institute of Cardiology, Warsaw, Poland
Abstract
No Abstract
References
- Eur Heart J. 2000;21:15371546
[Abstract/Free Full Text] - Tognoni G. The EMIP Project. Eur Heart J. 2000;21:14981499
[Free Full Text] - Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl CoA thiolase. Circ Res. 2000;86:580588
[Abstract/Free Full Text] - Szwed H, Sadowski Z, Elikowski W. Efficacy and safety of trimetazidine in combination with metoprolol in patients with stable effort angina pectoris. TRIMPOL-II-double-blind, randomized, placebo-controlled, multicentre trial. Eur Heart J. 2000;21:363
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||